A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs AbGn 107 (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Proof of concept
- Sponsors AbGenomics Corporation
- 23 Aug 2019 Planned number of patients changed from 116 to 136.
- 29 Nov 2018 Planned number of patients changed from 54 to 116.
- 29 Nov 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2020.